Skip to content

A Comparative Study Evaluating Pain Experienced During Intrauterine Device Insertion in Women

A Regional, Multicenter Comparative Study Evaluating Pain Experienced During Intrauterine Device Insertion in Women According to Their Parity

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07437235
Acronym
DODIU
Enrollment
162
Registered
2026-02-27
Start date
2021-06-23
Completion date
2023-03-30
Last updated
2026-02-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intrauterine Contraceptive Device Complication

Keywords

pain assessment, nulliparous/multiparous parity

Brief summary

The intrauterine device (IUD) is a reversible contraceptive method with good efficacy and long-lasting action. One of the obstacles to IUD insertion, both for healthcare professionals and patients, is the fear of painful insertion. There is little data in the literature on the pain experienced by patients, and even less in relation to their parity. Several studies have been conducted and show that nulliparous women seemed to experience more intense pain compared to multiparous women (2.7 vs 1.9 p\<0.05)

Detailed description

The hypotheses of this study are: * Pain is more intense in nulliparous women than in multiparous women. * Nulliparous women are more anxious before IUD insertion than multiparous women. * Satisfaction rates at 6 and 12 months do not differ according to parity. Pain will be assessed at each stage of IUD insertion using a numerical pain scale from 0 to 10 for speculum insertion, Pozzi forceps insertion, and IUD insertion, by the patient herself. Pain will be reassessed 5 minutes after insertion, also by the patient. Patients' anxiety levels will be assessed before insertion using the Spielberger State Anxiety Scale. This is a self-administered questionnaire comprising 20 items. This is a 4-point Likert scale assessing the intensity of the subject's feelings ("no," "somewhat no," "somewhat yes," "yes"). The satisfaction rate will be assessed by telephone questionnaire at 6 and 12 months, allowing us to evaluate the continuation rate as well as potential side effects of this method of contraception, such as amenorrhea, spotting, headaches, or mastalgia. Based on the results, the aim of this study is to propose appropriate pain management and information to reduce any anxiety and reassure patients about their satisfaction with this method of contraception.

Interventions

None listed

Sponsors

University Hospital, Rouen
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients aged 18 or older * Patients desiring intrauterine device (IUD) contraception. * Patients without contraindications to the desired IUD contraception (uterine malformation, pregnancy, undiagnosed vaginal bleeding, current STI, Wilson's disease, uterine cancer, uterine fibroids, current phlebitis, breast cancer, hormone-sensitive condition, etc.). * Patients agreeing to participate in the study. * Patients agreeing to be contacted at 6 months and 1 year.

Exclusion criteria

* Patients under 18 years of age. * Patients 25 years of age or younger who have not been screened for Chlamydia and Gonorrhea prior to IUD insertion. * Patients with a contraindication to IUD insertion. * Patients with risk factors for sexually transmitted infections. * Patients with comprehension difficulties and/or a language barrier. * Patients who object to participating in the study. * Intrauterine device insertion by a practitioner in training (first insertion).

Design outcomes

Primary

MeasureTime frameDescription
The main objective of the study is to assess whether there is a significant difference between the pain experienced by nulliparous and multiparous women during the insertion of an intrauterine device.Day 1The primary evaluation criterion is the pain experienced at each stage of IUD insertion. This will be assessed using a numerical pain scale from 0 to 10 during the insertion of the speculum, Pozzi forceps, and intrauterine device, by the patient immediately after insertion. Pain 5 minutes after insertion is also assessed using the same method.

Secondary

MeasureTime frameDescription
Evaluate the criteria motivating the choice of intrauterine device contraception in multiparous patients.1 dayThe criteria motivating the choice of IUD contraception will be assessed using a closed-ended question containing 10 items, with multiple possible answers.
Evaluate the criteria motivating the choice of intrauterine device contraception in nulliparous patients.1 dayThe criteria motivating the choice of IUD contraception will be assessed using a closed-ended question containing 10 items, with multiple possible answers.
Assessing the stress generated by the insertion of an intrauterine device1 dayThe patient's anxiety level will be assessed before the procedure using the Spielberger State Anxiety Scale. This self-administered questionnaire comprises 20 items. It uses a 4-point Likert scale to evaluate the intensity of the subject's feelings ("no," "somewhat no," "somewhat yes," "yes"). Each response to an item is scored from 1 to 4, with 1 indicating the lowest level of anxiety and 4 the highest. The score is calculated by summing the scores obtained for each item. The score can therefore range from 20 to 80.
Evaluation of the rate of continued use at 6 months, then at 1 year during follow-up12 monthsThe satisfaction rate will be assessed by a telephone questionnaire at 6 and 12 months, allowing for an evaluation of the continuation rate. This involves measuring the percentage of women who are still using the contraceptive system at 6 and 12 months.
Evaluation of the side effects caused by this method of contraception during follow-up.12 monthsles potentiels effets secondaires engendrés par ce mode de contraception comme l'aménorrhée, la survenue de spotting, de céphalées, ou encore de mastodynie seront évalués par un questionnaire téléphonique à 6 mois et 12mois

Countries

France

Contacts

STUDY_DIRECTORIsabelle IM MOTTE, Doctor

Service de Gynécologie-Obstétrique

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 28, 2026